Activist investors target Evogene (NASDAQ: EVGN) board as ATM capacity rises
Rhea-AI Filing Summary
Evogene Ltd. reports increasing the maximum aggregate offering price of ordinary shares available under its at-the-market Sales Agreement with A.G.P./Alliance Global Partners from $2,926,500 to $3,288,113, enabling potential issuance of an additional $361,613 of ordinary shares, supported by a legal opinion.
The company also updates its risk factors to describe an ongoing campaign by activist shareholders who filed a Schedule 13D on July 10, 2026 and requested a shareholder meeting to replace most directors. Evogene states that such activism and any resulting proxy contest could materially and adversely affect its business, financial condition, results of operations and the market price of its ordinary shares, and incorporates this disclosure into certain existing registration statements.
Positive
- None.
Negative
- Activist campaign targeting board composition – Certain shareholders filed a Schedule 13D and demanded a shareholder meeting to remove all current directors except the CEO and install their nominees, which Evogene warns could materially and adversely affect its business, financial condition, results and share price.
Filing Explained
The activist shareholders’ July 10 demand remains unresolved: the filing gives no assurance that Evogene will call the requested meeting or that a shareholder vote or board change will occur.
Key Figures
New ATM offering capacity: $3,288,113
Previous ATM offering capacity: $2,926,500
Additional ATM capacity: $361,613
+2 more
5 metrics
New ATM offering capacity
$3,288,113
Maximum aggregate offering price of ordinary shares under the Sales Agreement after the increase on July 17, 2026
Previous ATM offering capacity
$2,926,500
Maximum aggregate offering price of ordinary shares under the Sales Agreement before the July 17, 2026 increase
Additional ATM capacity
$361,613
Dollar value of additional ordinary shares that may be sold under the Sales Agreement as a result of the increase
Schedule 13D filing date
July 10, 2026
Date certain shareholders filed a Schedule 13D and initiated the activist campaign
Report date
July 17, 2026
Date Evogene increased the ATM maximum aggregate offering price and signed the report
Key Terms
at-the-market offering, Sales Agreement, Schedule 13D, extraordinary general meeting, +1 more
5 terms
at-the-market offering financial
"increased the maximum aggregate offering price of its ordinary shares issuable under its at-the-market offering"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
Sales Agreement financial
"ordinary shares issuable under its Sales Agreement with A.G.P./Alliance Global Partners"
A sales agreement is a written contract that sets out the terms for selling goods, services, or assets, specifying price, delivery, payment schedule and responsibilities of each side. For investors it matters because it creates a predictable stream of revenue or cash obligations, clarifies timing and risk, and can change a company’s value or forecasts much like a signed order turns a customer’s verbal intent into a firm commitment.
Schedule 13D regulatory
"activist shareholders who have filed a Schedule 13D with the SEC on July 10, 2026"
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
extraordinary general meeting regulatory
"demanded that we call an extraordinary general meeting of shareholders for the purpose of removing"
proxy contest regulatory
"These activities, whether or not they result in a formal proxy contest or a change in control"
A proxy contest occurs when shareholders try to influence a company's decisions by challenging the current management or board of directors, often by trying to gain enough support from other shareholders to make changes. It’s like a group of voters trying to sway an election by persuading others to support their preferred candidate or agenda. This process matters to investors because it can lead to significant changes in how a company is run, affecting its future direction and value.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What change did Evogene (EVGN) make to its at-the-market offering?
Evogene increased the capacity of its at-the-market ordinary share offering to $3,288,113 from $2,926,500. This change applies under its existing Sales Agreement with A.G.P./Alliance Global Partners and allows additional ordinary shares to be sold within that dollar limit.
How much additional at-the-market capacity did Evogene (EVGN) add?
Evogene added $361,613 of additional ordinary shares, measured by aggregate offering price, to its at-the-market program. A legal opinion from Meitar | Law Offices covers the legality of issuing these extra shares under the existing Sales Agreement framework.
Which Evogene (EVGN) registration statements incorporate this disclosure?
The disclosure is incorporated by reference into Evogene’s Form F-3 registration statements (File Nos. 333-277565 and 333-294650) and multiple Form S-8 registration statements, so the updated risk factor and ATM increase apply to those registered securities.